Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to ...

Maxim Group analyst Matthew Galinko maintained a Buy rating on SEALSQ Corp (LAES – Research Report) yesterday and set a price target of $6.00.

Fintel reports that on March 25, 2025, Maxim Group downgraded their outlook for CNS Pharmaceuticals (NasdaqCM:CNSP) from Buy ...

Maxim Group analyst Tate Sullivan maintained a Buy rating on Icon Energy Corp. (ICON – Research Report) yesterday and set a price target of ...

Maxim Group reissued their hold rating on shares of CNS Pharmaceuticals (NASDAQ:CNSP – Free Report) in a report issued on ...

Fintel reports that on March 24, 2025, Maxim Group upgraded their outlook for ... holds 125K shares representing 0.98% ownership of the company. In its prior filing, the firm reported owning ...

Fintel reports that on February 27, 2025, Maxim Group initiated coverage of STRATA ... See our leaderboard of companies with the largest price target upside. The projected annual revenue for ...

Maxim Group assumed coverage on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a research note released on Friday, Marketbeat reports. The firm issued a buy rating and a $10.00 price ...